Halma (LON:HLMA) Rating Reaffirmed
JP Morgan Cazenove now has a GBX 700.00 Estimated Target Price on the 3.21 billion GBP market cap company or -17.70% downside potential. In analysts note made public on Friday morning, Halma (LON:HLMA) shares have had their “Underweight” Rating reaffirmed by investment advisers at JP Morgan Cazenove.
From a total of 10 analysts covering Halma PLC (LON:HLMA) stock, 4 rate it a ”Buy”, 2 a “Sell”, and 4 a ”Hold”. This means that 40% of the ratings are positive. The highest target price is GBX 925 while the lowest target price is GBX 700. The mean of all analyst targets is GBX 792.2 with a -9.30% below today’s (GBX 858) stock price. Halma PLC was the topic of 29 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. JP Morgan maintained shares on December 4 with “Underweight” rating. Barclays Capital maintained shares with “Equal Weight” rating and GBX 715 target share price in a report from a November 18. Jefferies maintained HLMA stock in a recent report from November 25 with “Buy” rating. Investec maintained the rating on November 17. Investec has a “Hold” rating and a GBX 785 price target on shares. Finally, BNP Paribas maintained the stock with “Outperform” rating in a report issued on a November 18.
Approximately 271,373 shares of stock traded hands. Halma plc (LON:HLMA) has risen 18.19% since May 7, 2015 and is uptrending. It has outperformed by 20.98% the S&P500.
Halma plc is a United Kingdom-based company, which is engaged in developing products that secure and protect the elements critical to lives. The company has a market cap of 3.21 billion GBP. The Company’s products save lives, prevent injuries, and protect people and assets around the world. It has 30.44 P/E ratio. The Firm operates in four divisions: Process Safety, which provides products that protect assets and people at work; Infrastructure Safety, which includes products that detect hazards to protect assets and people in public spaces and commercial buildings; Medical, which includes products that improve personal and public health, and Environmental & Analysis, which includes products and technologies for analysis in safety, life sciences and environmental markets.